Select Bibliography

Filter by any of these (after searching):

Johnson, J L

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 2 items

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

Bartlett, N L , Niedzwiecki, D , Johnson, J L , Friedberg, J W ... - - Ann Oncol - 2007

Manuscript - Primary - Primary - Lymphoma - CALGB-59804

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.

Czuczman, M S , Leonard, J P , Jung, S , Johnson, J L , Hsi, E D ... - - Ann Oncol - 2012

Manuscript - Primary - Primary - Lymphoma - CALGB-50402